Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial-Reference-Cited by-同舟云学术

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

Published:2013-02-20 Issue:1 Volume:11 Page:
ISSN:1741-7015
Container-title:BMC Medicine
language:en
Short-container-title:BMC Med

Author:

Bailey Clifford J,Gross Jorge L,Hennicken Delphine,Iqbal Nayyar,Mansfield Traci A,List James F

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1186/1741-7015-11-43.pdf

Reference18 articles.

1. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009, 32: 193-203. 10.2337/dc08-9025.

2. Bailey CJ, Turner RC: Metformin. N Engl J Med. 1996, 334: 574-579. 10.1056/NEJM199602293340906.

3. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M: Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009, 85: 513-519. 10.1038/clpt.2008.250.

4. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Geraldes M, Li L, Pfister M: Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009, 85: 520-526. 10.1038/clpt.2008.251.

5. List JF, Woo V, Morales E, Tang W, Fiedorek FT: Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009, 32: 650-657. 10.2337/dc08-1863.

Cited by 277 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A meta‐analysis of randomized controlled studies examining the effects of sodium‐glucose co‐transporter‐2 inhibitors on peripheral artery disease and risk of amputations;Diabetes, Obesity and Metabolism;2024-09-12

2. Sodium–glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes;Journal of Diabetes Investigation;2024-09-10

3. SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials;Journal of Cardiovascular Electrophysiology;2024-06-28

4. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes;Cochrane Database of Systematic Reviews;2024-05-21

5. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians;Annals of Internal Medicine;2024-05